Health Canada Oks Vertex’s CASGEVY, First CRISPR/Cas9 Gene-Edited Therapy For Sickle Cell Disease
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene autotemcel), an autologous genome edited hematopoietic stem cell-based therapy, for the treatment of patients 12 years of age and older with sickl
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1486127040-2d871407d82744269fa20ef56224f5ef.jpg "Where Can You Buy Netspend Cards?")
:max_bytes(150000):strip_icc():format(jpeg)/ABeginnersGuidetoCallBuying-e0433db389da44ebb6dee9682d72e612.jpg "A Beginner’s Guide to Call Buying")
